Anti-CD20 monoclonal antibody therapies in relapsing multiple sclerosis: A systematic review and meta-analysis of randomised controlled trials.

Alatawi A, Al-Dhahi AS, Alatawi A, Almaser S

Open source

DOI
10.1016/j.msard.2026.107919
Published
2026 Sep 9
Container
Multiple sclerosis and related disorders
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.msard.2026.107919,
  title = {Anti-CD20 monoclonal antibody therapies in relapsing multiple sclerosis: A systematic review and meta-analysis of randomised controlled trials.},
  author = {Alatawi A and Al-Dhahi AS and Alatawi A and Almaser S},
  year = {2026},
  journal = {Multiple sclerosis and related disorders},
  doi = {10.1016/j.msard.2026.107919},
  url = {https://doi.org/10.1016/j.msard.2026.107919}
}

RIS

TY  - JOUR
TI  - Anti-CD20 monoclonal antibody therapies in relapsing multiple sclerosis: A systematic review and meta-analysis of randomised controlled trials.
AU  - Alatawi A
AU  - Al-Dhahi AS
AU  - Alatawi A
AU  - Almaser S
PY  - 2026
JO  - Multiple sclerosis and related disorders
DO  - 10.1016/j.msard.2026.107919
UR  - https://doi.org/10.1016/j.msard.2026.107919
ER  - 

APA

A, A., AS, A., A, A., & S, A. (2026). Anti-CD20 monoclonal antibody therapies in relapsing multiple sclerosis: A systematic review and meta-analysis of randomised controlled trials.. Multiple sclerosis and related disorders. https://doi.org/10.1016/j.msard.2026.107919

Source records